AVITA Medical, Inc. (RCEL) EBIT (2018 - 2026)

AVITA Medical (RCEL) has reported EBIT for 9 consecutive years, with -$6.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 38.51% year-over-year to -$6.9 million; the trailing twelve-month figure through Jun 2026 stood at -$37.6 million (up 19.63% YoY), and the FY2025 full-year result was -$42.5 million, up 24.84% from the prior year.
• EBIT advanced to -$6.9 million in Q2 2026 per RCEL's latest filing, from -$10.4 million in the prior quarter.
• Across five years, EBIT topped out at -$5.7 million in Q3 2022 and bottomed at -$17.2 million in Q1 2024.
• Historically, EBIT has averaged -$10.9 million across 5 years, with a median of -$10.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: EBIT jumped 65.47% in 2022, then tumbled 73.61% in 2024.
• Over 5 years, EBIT stood at -$9.9 million in 2022, then decreased by 23.97% to -$12.3 million in 2023, then climbed by 18.87% to -$10.0 million in 2024, then decreased by 4.53% to -$10.4 million in 2025, then surged by 34.14% to -$6.9 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$6.9 million, -$10.4 million, and -$9.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.